INFLANET - A French Network for PET imaging of neuroinflammation in MS
EU CTIS ID: 2023-510304-53-00
What this study is testing
To quantify, in a multicentre trial applying [18F]-DPA-714 PET, the smoldering component of white matter lesions in people with multiple sclerosis (PwMS), as compared with [18F]-DPA-714 binding in the white matter of healthy controls who underwent a PET acquisition with the same camera than patients in each center.
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- RRMS patients: - Age between 18 and 55 years old - RRMS according to the 2017 Mc Donald criteria - Last treatment with methylprednisolone should have been performed at least 1 month before PET examinations - No current disease modifying therapy or under platform therapy (dimethyl fumarate, teriflunomide, beta-interferons, glatiramer acetate)- Indication for a highly active disease modifying treatment: Natalizumab, anti CD20 antibody, Alemtuzumab, sphingosine-1 phosphate modulator, or cladribine. This will consist either as patients with an active form of relapsing MS or patients who have experienced two relapses during the previous year - Affiliation to a social security scheme or beneficiary of such a scheme (except “Aide Médicale d’Etat”) Healthy Volunteers: - Age between 18 and 55 years old - Without any evolutive pathology - Able to understand the study objectives and procedures - Affiliation to a social security scheme or beneficiary of such a scheme (except “Aide Médicale d’Etat”)
You likely can't join if
- all participants: - Any reasons, which does not allow to perform MRI, including claustrophobia, the implant of a pace-maker or the presence of an intra-ocular foreign body, (a contra-indication questionnaire will be filled in beforehand) - PET for clinical research already done within the last 12 months - Low Affinity Binding profile (analyse of TSPO polymorphism done at screening visit) - Pregnancy, breast-feeding, lack of efficient contraception for women of childbearing potential - Current symptoms of severe or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary or cardiac disease, or any other chronic neurological diseases - Unwillingness to be informed in case of unexpected MRI abnormality (with a significant medical anomaly) - Patient under legal protection - Participation in another interventional study or being in the exclusion period at the end of a previous study RRMS patients: - hypersensitivity to gadoteric acid - meglumine or any drug containing gadolinium - Severe renal insufficiency (creatinine clearance < 60mL/min and GFR <30ml / min / 1.73m2).
The study team makes the final eligibility decision.
Where it's taking place
- France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from EU CTIS. The study team decides eligibility, and your own doctor gives medical advice.